Home Carboxys 4-Quinolinecarboxylic acid,6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-, sodium salt

4-Quinolinecarboxylic acid,6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-, sodium salt

CAS No.:
96201-88-6
Catalog Number:
AG00IMLN
Molecular Formula:
C23H14F2NNaO2
Molecular Weight:
397.3493
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
Product Description
Catalog Number:
AG00IMLN
Chemical Name:
4-Quinolinecarboxylic acid,6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-, sodium salt
CAS Number:
96201-88-6
Molecular Formula:
C23H14F2NNaO2
Molecular Weight:
397.3493
MDL Number:
MFCD22648381
IUPAC Name:
sodium;6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylate
InChI:
InChI=1S/C23H15F2NO2.Na/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25;/h2-12H,1H3,(H,27,28);/q;+1/p-1
InChI Key:
PZOHOALJQOFNTB-UHFFFAOYSA-M
SMILES:
Fc1ccc2c(c1)c(C(=O)[O-])c(c(n2)c1ccc(cc1)c1ccccc1F)C.[Na+]
UNII:
49EEF6HRUS
Properties
Complexity:
557  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
397.089g/mol
Formal Charge:
0
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
397.357g/mol
Monoisotopic Mass:
397.089g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
53A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold. European journal of medicinal chemistry 20120301
Potent antiviral activity of brequinar against the emerging Cantagalo virus in cell culture. International journal of antimicrobial agents 20111101
The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites. Biochemistry 20080826
Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans. The FEBS journal 20060701
Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase. Bioorganic & medicinal chemistry letters 20060315
Dual binding mode of a novel series of DHODH inhibitors. Journal of medicinal chemistry 20060223
Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase. Bioorganic & medicinal chemistry 20050315
Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein science : a publication of the Protein Society 20040401
Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. The Journal of biological chemistry 20021101
In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine. Scandinavian journal of immunology 20020701
Inhibition of cyclosporin-resistant B-cell antigen responses by pyrazoles: a tool for the identification of novel molecular mechanisms of B-cell activation. Transplantation proceedings 20010501
Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase. Biochemistry 20010220
Anti-arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20010101
Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chemico-biological interactions 20000103
Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria. Biochemical pharmacology 19981015
2',3'-Didehydro-3'-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5'-triphosphate biosynthesis. Molecular pharmacology 19960701
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390). Cancer research 19890815
Properties